argenx(ARGX) Newsfilter·2025-02-20 06:00Company Overview - argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [3] - The company is known for developing and commercializing the first approved neonatal Fc receptor (FcRn) blocker, which is available in multiple regions including the U.S., Japan, Israel, the EU, the UK, China, and Canada [3] - argenx is actively evaluating its drug efgartigimod for multiple serious autoimmune diseases and is advancing several earlier-stage experimental medicines [3] Upcoming Events - argenx will host a conference call and audio webcast on February 27, 2025, at 2:30 PM CET (8:30 AM ET) to discuss its full year 2024 financial results and provide a fourth quarter business update [1] - The live call can be accessed via the Investors section of the argenx website, and a replay will be available for approximately one year [2] Contact Information - Media inquiries can be directed to Ben Petok via email [4] - Investor relations contacts include Alexandra Roy for the US and Lynn Elton for the EU [4]